ClinicalTrials.gov Search Results 03/19/2021

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol Participants With or Without Stable Comorbidities Associated With Progression to United States Popular Associated With Progression United States Popular Associated With Progression to United States Popular Associated With Progression United States Popular Associated With Progression United States Popular Associated With Progression United States Popular Associated With		Title	Status	Study Results	Conditions	Interventions	Locations
Arkansas, United States	1	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-		-	Participants With or Without Stable Co- morbidities Associated With Progression to Severe COVID-19 at Different Stages of	•Biological: Ad26.COV2.S	 Synexus Clinical Research US, Inc, Birmingham, Alabama, United States University of Alabama Birmingham, Birmingham, Alabama, United States Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States Optimal Research, Huntsville, Alabama, United States Synexus Clinical Research US, Inc, Glendale, Arizona, United States VA Medical Center, Phoenix, Arizona, United States Central Phoenix Medical Clinic, Phoenix, Arizona, United States Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States Synexus Clinical Research US, Inc, Tucson, Arizona, United States Synexus Clinical Research US, Inc, Tucson, Arizona, United States

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services